<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399008</url>
  </required_header>
  <id_info>
    <org_study_id>M102-21123</org_study_id>
    <nct_id>NCT01399008</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in Combination With Allopurinol in Gout Patients With an Inadequate Hypouricemic Response to Allopurinol Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in
      combination with allopurinol compared to allopurinol alone when administered orally once a
      day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Uric Acid</measure>
    <time_frame>Percent change from baseline in serum uric acid at Week 4</time_frame>
    <description>Percent change from baseline in serum uric acid in Per Protocol population</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arhalofenate 400 mg plus allopurinol 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arhalofenate 600 mg plus allopurinol 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus Allopurinol 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 300 mg as active comparator</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.6 mg colchicine daily as flare prophylaxis</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Known gout patients (per criteria of the American Rheumatism Association for the
             classification of the acute arthritis of primary gout

               1. Patients who have been taking at least 200 mg/day of allopurinol as the sole ULT
                  for at least two weeks with a sUA of ≥ 6.5 mg/dL and ≤ 12 mg/dL at screening and
                  ≥ 6.0 mg/dL and ≤ 12 mg/dL at Week -1 (Visit 2) randomization visit.

                  -OR -

               2. Patients who are not on ULT or are taking allopurinol &lt; 200 mg/day must have a
                  sUA ≥ 8.0 mg/dL and ≤ 12 mg/dL at screening and ≥ 6.0 mg/dL and ≤ 12 mg/dL at
                  Week -1 (Visit 2) randomization visit.

          2. Male or female, 18-75 years of age at screening

          3. All female patients must be surgically sterile or post-menopausal (at least 45 years
             of age with no history of menses for at least 2 years; or any age with no history of
             menses for at least six months and serum FSH ≥ 40 mIU/mL) or have a partner who has
             undergone vasectomy or must agree to use two medically accepted methods of
             contraception including a barrier method (see the list in Appendix 4) for the entire
             duration of the study unless she reports complete sexual abstinence.

          4. Female patients must not be pregnant or lactating.

          5. Male patients with a female partner of child-bearing potential must agree to use
             condoms or the partner must use a medically acceptable method of contraception for the
             entire duration of the study.

          6. Estimated creatinine clearance (CrCl) by Cockcroft-Gault method ≥ 60 mL/min at
             screening

          7. Serum creatinine value ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males

          8. Liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X
             ULN for GGT; and ≤ 3X ULN for CK

          9. All other clinical laboratory parameters must be within normal limits or considered
             not clinically significant for participation in this study.

         10. Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically
             significant for participation in this study.

         11. Systolic blood pressure ≤ 160 mm Hg and diastolic blood pressure ≤ 90 mm Hg; known
             hypertensive patients controlled with medications other than thiazide diuretics (blood
             pressure [BP] reading as above) may be included

        Exclusion Criteria:

          1. Treatment with any ULT other than allopurinol (e.g., probenecid, benzbromarone,
             febuxostat, or pegloticase) within 30 days of the Screening Visit

          2. Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder,
             or organ transplant)

          3. Diagnosis of xanthinuria

          4. History of documented or suspected kidney stones

          5. Known infection with HIV or history of viral hepatitis type B or C

          6. History of illicit drug or alcohol abuse within 1 year of screening

          7. History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer
             disease (unless known H. pylori infection treated successfully without recurrence), or
             nephrotic syndrome within three years of screening

          8. History of stroke, TIA, acute MI, congestive heart failure (NYHA Class II-IV), angina
             pectoris, coronary intervention procedure (including but not limited to angioplasty,
             stent placement, coronary revascularization), lower extremity bypass procedure,
             systemic or intracoronary fibrinolytic therapy within five years of screening

          9. Malignancy (except treated basal cell carcinoma) within five years of screening

         10. BMI &gt; 42 kg/m2

         11. Current or expected requirement for anticoagulant therapy (except for aspirin ≤ 325
             mg/day)

         12. Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment

         13. Current or expected treatment with potent CYP3A4 inhibitors (See Appendix 6),
             cytotoxic agents (azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.),
             ranolazine, digoxin, theophylline, sulphonylureas, thiazolidinediones, diuretics,
             atypical antipsychotic agents, ampicillin, amoxicillin or phenytoin

         14. Chronic treatment with NSAIDs (use to treat acute flares are permitted).

         15. Current or expected treatment with systemic corticosteroids (except topical,
             ophthalmic, intra-articular, or inhaled at a dose &lt; 1600 μg/day) other than to treat
             acute flare

         16. Known hypersensitivity to allopurinol, colchicine, or aspirin

         17. Treatment with any other investigational therapy within the 30 days prior to
             screening, or patients who received at least one dose of study drug while enrolled in
             any previous or concomitant MBX-102 trial

         18. Any other condition that compromises the ability of the patient to provide informed
             consent or to comply with the objectives and procedures of this protocol, as judged by
             the investigator and/or medical monitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tiblisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2011</study_first_posted>
  <results_first_submitted>March 20, 2014</results_first_submitted>
  <results_first_submitted_qc>July 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2014</results_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Upon completion of screening all patients will enter into a 3-week run-in/stabilization period starting at Week -3 (Visit 1). During this phase, all patients will take allopurinol 300 mg once daily. In addition, patients will be given colchicine 0.6 mg once daily until the final study visit as prophylaxis to prevent potential gout flares.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arhalofenate 400 mg</title>
          <description>Arhalofenate 400 mg plus allopurinol 300 mg</description>
        </group>
        <group group_id="P2">
          <title>Arhalofenate 600 mg</title>
          <description>Arhalofenate 600 mg plus allopurinol 300 mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo plus Allopurinol 300 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arhalofenate 400 mg</title>
          <description>Arhalofenate 400 mg plus allopurinol 300 mg</description>
        </group>
        <group group_id="B2">
          <title>Arhalofenate 600 mg</title>
          <description>Arhalofenate 600 mg plus allopurinol 300 mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo plus Allopurinol 300 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="10.9"/>
                    <measurement group_id="B2" value="50.6" spread="10.2"/>
                    <measurement group_id="B3" value="50.4" spread="11.0"/>
                    <measurement group_id="B4" value="51.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Uric Acid</title>
        <description>Percent change from baseline in serum uric acid in Per Protocol population</description>
        <time_frame>Percent change from baseline in serum uric acid at Week 4</time_frame>
        <population>Per Protocol population (all randomized patients who received at least 1 dose of blinded study drug, had at least 1 post-treatment evaluation, had not violated any major entry criterion likely to confound an efficacy analysis and had not deviated significantly from the protocol between enrollment and study completion).</population>
        <group_list>
          <group group_id="O1">
            <title>Arhalofenate 400 mg</title>
            <description>Arhalofenate 400 mg plus allopurinol 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Arhalofenate 600 mg</title>
            <description>Arhalofenate 600 mg plus allopurinol 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo plus Allopurinol 300 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Uric Acid</title>
          <description>Percent change from baseline in serum uric acid in Per Protocol population</description>
          <population>Per Protocol population (all randomized patients who received at least 1 dose of blinded study drug, had at least 1 post-treatment evaluation, had not violated any major entry criterion likely to confound an efficacy analysis and had not deviated significantly from the protocol between enrollment and study completion).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="20.9"/>
                    <measurement group_id="O2" value="-9.9" spread="17.1"/>
                    <measurement group_id="O3" value="-9.5" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks (Treatment/Post Treatment Periods)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arhalofenate 400 mg Plus Allopurinol 300 mg</title>
          <description>Arhalofenate 400 mg plus allopurinol 300 mg (Safety Population)</description>
        </group>
        <group group_id="E2">
          <title>Arhalofenate 600 mg Plus Allopurinol 300 mg</title>
          <description>Arhalofenate 600 mg plus allopurinol 300 mg (Safety Population)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Plus Allopurinol 300 mg</title>
          <description>Placebo plus allopurinol 300 mg (Safety Population)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Gout flare</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication requires the prior written consent of the Sponsor. The Principal Investigator must provide the Sponsor the opportunity to review any proposed abstracts, manuscripts or presentations that relate to any research or clinical results at least 30 days prior to its intended submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Jean Stempien, M.D., Acting Chief Medical Officer</name_or_title>
      <organization>Metabolex</organization>
      <phone>510-293-8800</phone>
      <email>mjstempien@metabolex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

